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A B S T R A C T
Background: Immunoglobulin (IG) replacement therapy in patients with primary immunodeﬁciency diseases
(PID) can be administered daily to every 2 weeks subcutaneously (SCIG) or every 3 or 4 weeks intravenously
(IVIG).
Objectives: Develop a population pharmacokinetic (PK) model simulating IG exposure with Ig20Gly, a 20% SCIG;
determine the dose adjustment factor for Ig20Gly relative to IVIG.
Methods: Data from patients with PID treated with Ig20Gly and IVIG 10% were used to characterize IG popu-
lation PK by nonlinear mixed-eﬀects modeling and validated using data splitting and a visual predictive check.
IG proﬁles were simulated for 1000 patients/interval treated with Ig20Gly (daily, every 2 days, every 3 days,
twice weekly, weekly, every 2 weeks). An Ig20Gly adjustment factor of 130% was used to simulate Ig20Gly to
IVIG AUC ratios for weekly or every 2 weeks Ig20Gly dosing intervals and a monthly IVIG dosing interval.
Results: A 1-compartment model, using weight as a covariate on clearance, derived from an index modeling
dataset (n=81) demonstrated predictability for a validation dataset (n= 21). The model estimate of bioa-
vailability was 73.9%. Simulations for 6 dosing intervals showed similar mean proﬁles with overlapping pre-
diction intervals. Mean AUC ratios of Ig20Gly to IVIG with a dose adjustment factor of 1.30:1 were 98.7% for
weekly and 97.7% for twice-weekly administration demonstrating comparable exposure.
Conclusion: Ig20Gly exposures from daily to up to every 2 weeks appeared equivalent. A 1.30 conversion factor
provided coverage comparable to IVIG when Ig20Gly is administered daily to every 2 weeks.
1. Introduction
Life-long immunoglobulin (IG) replacement therapy is required in
patients with primary immunodeﬁciency diseases (PID) characterized
by absent or deﬁcient antibody production that results in recurrent or
unusually severe infections [1]. IG replacement therapy can be ad-
ministered subcutaneously (SCIG) daily to every 2 weeks or in-
travenously (IVIG) at dosing intervals of 3 to 4 weeks with equivalent
eﬃcacy. However, compared with IVIG, SCIG oﬀers the advantages of
self-infusion at home, does not require venous access, and is associated
with a lower risk of systemic adverse events [2–4]. There are also key
pharmacokinetic (PK) diﬀerences between SCIG and IVIG administra-
tion. IVIG is infused directly into the intravascular space, resulting in an
early, high peak of IG concentration followed by a redistribution phase,
whereas SCIG must ﬁrst diﬀuse through the lymphatic system into the
bloodstream, resulting in a more gradual and stable increase in IG
concentration over 2 to 3 days without a high IgG serum peak [3,4].
Because bioavailability is lower with SCIG versus IVIG, the US Food and
Drug Administration (FDA) requires that the dose of SCIG be increased
to achieve equivalent immunoglobulin G (IgG) exposure between SCIG
and IVIG as measured by area under the concentration-time curve
(AUC) [3,4]. In the United States, current recommendations indicate
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that patients receiving SCIG should use a monthly dose that is 130% or
137% of their previous IVIG monthly dose, depending on the con-
centration of the SCIG product [5–9].
Ig20Gly (immune globulin subcutaneous [human], 20% solution
[Cuvitru™]; Baxalta US Inc., a member of the Takeda group of com-
panies, Lexington, MA, USA) is an SCIG product with an IgG con-
centration of 20% (w/v) that can be infused at rates up to 60mL/h/site.
Ig20Gly was shown to be eﬃcacious and well tolerated in two phase 2/
3 clinical trials in patients with PID conducted in Europe and North
America [10,11]. To further explore the bioavailability for Ig20Gly in
relation to IVIG, evaluate IgG levels under diﬀerent Ig20Gly dosing
schemes, and determine the most appropriate dose adjustment factor, a
population PK model was developed using data from these 2 trials.
2. Methods
The PK data for IG were obtained from 2 prospective, open-label,
non-controlled, multicenter phase 2/3 clinical trials evaluating Ig20Gly
in patients with PID conducted in North America (NCT01218438) and
Europe (NCT01412385) [10,11]. Details of the inclusion and exclusion
criteria and study design have been published previously [10,11]. In
brief, patients were aged ≥2 years with a documented diagnosis of
humoral immunodeﬁciency for which they had been receiving a stable
monthly equivalent dose of IG (SC or IV) at an average minimum dose
equivalent of 300mg/kg body weight every 4 weeks and a maximum
dose equivalent to 1000mg/kg body weight every 4 weeks for
≥3months before enrollment and had a serum IgG trough level >
500mg/dL at screening. The European trial consisted of 2 periods.
During period 1, patients received IVIG 10% for 13 weeks or SCIG 16%
for 12 weeks to attain a stable baseline serum IgG before starting
Ig20Gly treatment. In period 2, patients received Ig20Gly for 52 weeks
at an equivalent dose [11]. The North American trial had 4 study
periods. During period 1, all patients received IVIG 10% for 13 weeks to
determine the AUC for IgG after IVIG treatment. During periods 2 to 4,
patients received Ig20Gly. In period 2, Ig20Gly was administered in
some patients at a dose adjusted to 145% of IVIG dose for approxi-
mately 12 to 16weeks to assess equivalence in exposure, and in period
3, all patients received the same adjusted dose for 12 weeks. All patients
received Ig20Gly at individually adapted doses during period 4 for
40 weeks [10].
In both trials, IgG trough levels were assessed in all patients at de-
ﬁned time points throughout the course of each study period, with some
additional serial sampling collections for patients aged ≥12 years.
Serum IgG concentrations were determined using a validated enzyme-
linked immunosorbent assay–based method in an accredited laboratory
setting.
Patients were considered for population PK modeling if they had
accurate dosing histories and sampling collection information (date and
time), along with ≥2 measurable IgG concentrations for a modeled IG
product and for Ig20Gly. Data from both studies were pooled and a
random data splitting approach was used to create an index data set for
model development containing 80% of the total number of evaluable
patients from both studies, and a validation data set for model valida-
tion consisting of the remaining 20% of patients (only included data
from the North American study) [12]. Anticipating the eﬀect of weight
on IgG PK, the data splitting was stratiﬁed based on age. All modeling
was based on simultaneous ﬁts to both Ig20Gly and IVIG data. Given
that patients were required to be on stable therapy before the study,
steady-state conditions were assumed, with the baseline being a com-
bination of both endogenous and exogenous IgG.
2.1. Pharmacokinetic model development
2.1.1. Base model development
The population PK of total IgG concentration data collected was
characterized by nonlinear mixed-eﬀects modeling using NONMEM,
version VI, level 1.0. The base model for total IgG was identiﬁed by
comparing diﬀerent structural PK models (eg, 1-compartment, 2-com-
partment) and screening various error models when appropriate. First-
order conditional estimation with interaction was used during model
development, with model selection based on reduction in objective
function value (OFV), Akaike Information Criterion (AIC), goodness-of-
ﬁt parameters, and goodness-of-ﬁt plots. Reduction in OFV assessment
was based on the likelihood ratio test for nested models and AIC for
non-nested models. Inclusion of body weight was tested within the base
structural models based on allometric principles.
2.1.2. Covariate model development
The covariates screened were selected a priori and included age,
body weight, geographic region, race, and sex. Relationships between
continuous and categorical covariates (for categorical covariates, only
where the group contained> 10% of the overall speciﬁc covariate
data), PK parameters, and interindividual variability were examined
before covariate development and then tested in a stepwise fashion. The
forward stepwise-based approach for the covariate search algorithm
used a P value of< 0.01 as the criterion for statistical signiﬁcance and a
more stringent P value of< 0.005 to minimize the risk of false-positives
for backward elimination. The covariate model demonstrating the
greatest improvement in the population PK model was incorporated
into the base population PK model, and remaining candidate covariates
were reevaluated incrementally. All methods of this analysis followed
the published guidelines suggested by the FDA for the analysis of po-
pulation PK data [12].
2.2. Model evaluation and quantiﬁcation
The model was evaluated for stability and predictability. A condi-
tion number of< 400 was used to indicate model stability of the
parameter estimates in addition to performing a nonparametric boot-
strap [13]. Final covariate model predictability was evaluated by visual
predictive check. The ﬁnal model predictability was further assessed by
comparing estimates between the index and validation data sets. Per-
formance of the ﬁnal NONMEM model was based on the evaluation of
the individual patient parameters and the mean prediction errors of
concentrations [14,15].
2.3. Dosing interval simulations
The model was used to evaluate alternative dosing intervals and
conversion factors. Random resampling with replacement from the
index set was used to create a 1000-patient population for each simu-
lation, which was used to generate predicted mean and 90% prediction
intervals for steady-state IgG concentration-time proﬁles for 6 alter-
native dosing intervals (daily, every other day, every third day, twice
weekly, weekly, or every 2 weeks). Simulations were divided by study
because the North American study had an individualized dosing scheme
for Ig20Gly, whereas in the European study, Ig20Gly was administered
in monthly doses equivalent to the IVIG dose.
2.4. Conversion factor simulations
Simulations were also conducted to explore Ig20Gly exposure using
dosing conversion factors based on the estimated bioavailability by
resampling 1000 patients from the index set based on the study start
IVIG dosing amounts assumed over 1month of administration.
Investigated dose levels included an adjustment factor for Ig20Gly of
130%, with a target of Ig20Gly≤137%, which would achieve exposure
with weekly administration equivalent to levels after IVIG administra-
tion. Individual Ig20Gly to IVIG 10% AUC ratios were calculated from
simulated steady-state IgG proﬁles over a monthly IV dosing interval
and weekly or every 2 weeks Ig20Gly dosing intervals.
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3. Results
3.1. Model development and evaluation
A total of 2063 IgG concentrations (Ig20Gly, n= 1302; IVIG 10%,
n=761) from 102 evaluable patients (European study, n=32; North
American study, n=70; Table 1) were identiﬁed for inclusion. Sub-
sequently, of the 1657 concentration samples provided by 81 patients
(1056 for Ig20Gly, 601 for IVIG) available for index set modeling
(~80% of the available data), 7 concentration samples were removed
for inaccurate or incomplete information from the index set (2 for
Ig20Gly, 5 for IVIG). The remaining ~20% of the data (from 21 patients
consisting of 406 samples [Ig20Gly, n= 246; IVIG 10%, n=160])
comprised the validation set. Fig. 1 depicts observed IgG levels pre-
sented by route (SC and IV) and study region (Europe and North
America), with a local weighted trend line for graphical illustration of
the data used for modeling. It includes all of the observed data collected
in both studies across all parts of the trials. Observed IgG levels were
higher in the North American study because, as noted in the methods,
this study used a dose-adjustment design in which some patients were
administered Ig20Gly at a dose adjusted to 145% of the IVIG dose.
The ﬁnal covariate model was a 1-compartment model with inter-
individual variability (IIV) on clearance (CL), central compartment
volume (V), and bioavailability (F1), including an oﬀ-directional cor-
relation term between CL and V, with a proportional residual error
model that adequately described Ig20Gly and IVIG 10% PK. The po-
pulation parameter estimates for F1, CL, and V were estimated as
73.9%, 0.00384 L/h, and 4.01 L, respectively. The ﬁrst-order absorption
rate constant was ﬁxed at 0.004 L/h and derived from the known time
to maximum concentrations after extravascular administration. The oﬀ-
diagonal correlation was estimated to be 0.507 and proportional error
was estimated to be 5.3%.
The eﬀect of bodyweight on CL led to the largest drop in the ob-
jective function for forward covariate step 1. Body weight was added as
a covariate on CL as shown below:
⎜ ⎟= × ⎛
⎝
⎞
⎠
L h L h weight kg
kg
CL ( / ) 0.00384 /
70
0.576
The addition of body weight as a covariate on CL resulted in a
substantial decrease of IIV of CL from 50.9% to 27.6%, with residual
variability unchanged. Given the correlation estimated between CL and
V, the IIV estimate for V also decreased substantially from 49.7% to
39.2%. The eﬀects of gender on CL and V and of age on CL were tested
in a second step. Possibly due to the known correlations of gender and
age with body size, including these variables as covariates did not im-
prove the model ﬁt.
3.1.1. Internal validation
No issues were noted regarding precision or stability with a relative
standard error on all structural parameters of< 10%, IIV parameters
Table 1
Baseline demographics.
Parameter All evaluable patients
(N=102)
Sex, n (%)
Male 57 (55.9)
Female 45 (44.1)
Race, n (%)
White 95 (93.1)
Black 3 (2.9)
Asian 2 (2.0)
Other 2 (2.0)
Age, y
Mean (SD) 32.1 (22.9)
Median (min, max) 30.0 (2.0, 83)
< 12 y, n (%) 26 (25.5)
≥12 y, n (%) 76 (74.5)
Weight, kg
Mean (SD) 62.8 (28.2)
Median (min, max) 63.7 (13.2, 161.8)
Baseline IgG concentration, g/L
Mean (SD) 10.2 (3.0)
Median (min, max) 9.9 (3.4, 19.9)
IgG= immunoglobulin G; SD= standard deviation.
Fig. 1. Observed IgG concentrations over time by study and treatment for all samples overlaid with a loess smooth for varied presentations. EU=European Union;
IgG= immunoglobulin G; IVIG= intravenous immunoglobulin; NA=North American.
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of< 48.9%, and a condition number of 23.7. Bioavailability, the key
parameter in the current context, was estimated as 74%, 73.4%, and
73.9% from the index data set, the full data set, and the median boot-
strap estimate, respectively, demonstrating model stability and in-
dicating agreement across the populations of patients. Model predict-
ability was demonstrated using a visual predictive check showing the
bulk of the observed concentrations were contained within the 95%
prediction interval, indicating the ﬁnal model suﬃciently predicted the
observed data and was robust for trough concentration prediction
(Fig. 2).
3.1.2. Validation based on data splitting
The ﬁnal population PK model derived from the index model de-
velopment data set successfully predicted the measured total IgG con-
centrations in the validation data set (ie, mean standardized mean
prediction error was not statistically signiﬁcantly diﬀerent from zero,
P=0.3222 [t-test]; using previously described methods [14,15]).
3.2. Simulation of IgG exposure following Ig20Gly administration daily,
every 2 days, every 3 days, twice weekly, weekly, or every 2 weeks
Simulations of total IgG concentrations for Ig20Gly administered
daily, every 2 days, every 3 days, twice weekly, weekly, and every
2 weeks using the resampled 1000 patients showed similar mean pro-
ﬁles with overlapping prediction intervals (Fig. 3). Compared with
weekly administration, administration every 2 weeks of Ig20Gly at
double the weekly dose predicted comparable IgG exposure. Ig20Gly
infusions given 2 to 7 times per week were predicted to produce IgG
exposures comparable to administration every 2 weeks.
Simulations of Ig20Gly exposure based on the estimated bioavail-
ability of 74% using the resampled 1000-patient data (based on the
IVIG level) showed the mean monthly equivalent dose (CV%) was
511mg/kg/mo (31%).
The model-based simulation showed that weekly or every-2-week
Ig20Gly administration at 130% of the monthly IVIG dose adequately
maintained IgG exposure (median AUC0–28 day ratios of 96.0% for
weekly and 95.8% for every-2-week dosing compared with IVIG
monthly dosing; Table 2). Graphs depicting total IgG concentration-
time proﬁles for weekly and every-2-week dosing of Ig20Gly at 130% of
the IVIG dose conﬁrm the comparable exposure achieved with a dose
conversion factor of 1.30 with weekly or every-2-week Ig20Gly ad-
ministration (Fig. 4A and B, respectively).
4. Discussion
The model developed from PK data from two phase 2/3 clinical
trials in patients with PID treated with Ig20Gly was a 1-compartment
model with IIV on CL, V, and F1, with a proportional residual error
model and a correlation between CL and V. This model oﬀered the best
ﬁt for the pooled analysis from two clinical trials, even though IG ki-
netics are often described using 2-compartment structural models. This
is likely due to several factors, including design factors (all samples
were collected at steady-state) and dose adjustments that were unique
to North America. An additional factor for that could account for po-
tential diﬀerences from the anticipated PK structural model was the
potential limitation of sampling in patients< 12 years of age who could
only contribute trough concentrations. This was also a likely con-
tributing factor for imprecision in the estimation of the absorption rate
constant (Ka). Consequently, the population Ka was ﬁxed to a value
derived based on steady-state time to peak concentration (Cmax),
leading to relatively ﬂat concentration proﬁles. It is important to note
that dose is a study design factor, with diﬀerences driven by the prac-
tice standards of the country. The model used in this analysis is a
function of the dosage and the corresponding IgG level. The model built
in this analysis and the published literature is linear. Therefore, dose
increases or decreases lead to proportional increases or decreases in IgG
levels. The wide range of doses included in the model allow for better
characterization of the actual doses being used in clinical practice and
for less extrapolation than if one were to try and apply one country's
model to another.
The 1-compartment model qualiﬁcation included multiple steps to
demonstrate the predictability and stability of the ﬁnal covariate
model. The data splitting approach conﬁrmed the ability of the model
to predict concentrations for patients not included in the modeling.
Likewise, the similarity of estimates achieved when the model was ﬁt to
all evaluable patients suggests the selected model was useful for reliable
extrapolation to the exposure, which would be achieved for varied
dosing intervals and diﬀerent dosing conversion factors.
The model estimate for Ig20Gly bioavailability of 73.9% was sup-
ported by bootstrap results. Berger et al. reported a mean bioavail-
ability of 66.7% from 4 diﬀerent SCIG products (Vivagloblin® [immune
globulin subcutaneous [human], 16% liquid; CSL Behring]; Gamunex®
[immune globulin injection [human], 10% caprylate/chromatography
puriﬁed; Grifols Therapeutics]; Gammagard™ [immune globulin infu-
sion [human], 10% solution; Baxalta US Inc.]; and Hizentra® [immune
globulin subcutaneous [human], 20% liquid; CSL Behring]) [16]. Si-
milarly observed decreased bioavailabilities among diﬀerent SCIG
products, relative to IVIG, are thought to reﬂect the subcutaneous route
of administration instead of speciﬁc product properties or the IgG
concentration [16].
In the Ig20Gly study conducted in Europe, a dose conversion for
Ig20Gly:IVIG was not used (ie, EMA requires that trough levels are
noninferior to those of IVIG and do not recommend an initial dose
adjustment) resulting in a bioavailability of Ig20Gly relative to IVIG
estimated as part of the clinical trial analysis of 82.07% [11], which
was higher than in this combined evaluation of EU and NA studies
where the latter contributed the majority of data in this evaluation. In
the Ig20Gly pivotal clinical trial conducted in North America, following
a 1.45 dose conversion (Ig20Gly:IVIG) and individual dose adjustment
(based on IG exposure [AUC] relative to IVIG 10%), Ig20Gly bioavail-
ability determined from the ratio of geometric means of the AUC while
on Ig20Gly treatment once per week versus IVIG 10% infusions (stan-
dardized to 1 week) was 1.09 [10]. This actual clinical trial result, in
conjunction with the model estimated bioavailability, suggested that a
Fig. 2. Ig20Gly visual predictive check of ﬁnal covariate model. Linear IgG
concentrations are shown after the start of the most recent infusion. The ma-
jority of the observed concentrations were contained within the 95% prediction
CI suggesting that the ﬁnal model suﬃciently predicts the observed data and
was robust for trough concentration prediction. EU=European Union;
IgG= immunoglobulin G; NA=North American.
T. Dumas, et al. International Immunopharmacology 71 (2019) 404–410
407
Ig20Gly exposure comparable to IVIG might be achieved using a lower
dosing conversion factor than what was initially thought. In parallel
with this view, subsequent simulations based on the Ig20Gly population
PK model conﬁrmed daily to every-2-week Ig20Gly administration of
the same monthly dose (ie, keeping the IG dose over the month constant
for the diﬀerent dosing frequencies) resulted in similar systemic ex-
posure to IgG at steady state where comparable systemic exposures to
IV administration can be achieved with a dose-conversion factor of
1.30.
Our data are consistent with the Ig20Gly dose adjustment in the
FDA label (dose adjustment factor of 1.30) [6]; the FDA recommends a
conversion factor that achieves equivalent systemic IG exposure (AUC)
for SCIG and IVIG. PK modeling for another SCIG 20% product,
IgPro20, utilized a 2-compartment model to simulate varied dosing
regimens. This 2-compartment model estimated 66% population bioa-
vailability and also predicted that the same total weekly dose could be
administered at diﬀerent intervals, from daily to every 2 weeks, pro-
viding equivalent systemic IgG exposure as IVIG dosing [17,18]. Si-
mulations with this model estimated equivalent IgG exposure with a
dose adjustment factor of 1.53 when switching to every-2-week dosing
of IgPro20 from monthly IVIG; however, a dose adjustment ratio of 1:1
with IgPro20 given every 2 weeks reduced systemic IgG exposure (AUC)
by 20% and Cmax by 45% compared with a single IVIG dose every
4 weeks [17]. Additional PK modeling and simulations of IgPro20
Fig. 3. Simulated mean and 90% prediction intervals for steady-state total IgG concentrations after Ig20Gly administration under varied dosing intervals (daily, every
2 days, every 3 days, twice weekly, weekly, or every 2 weeks) in the (A) European (EU) or (B) North American (NA) populations. 2×/wk.= twice weekly;
BIW=every 2weeks; IgG= immunoglobulin G; Q2D=every 2 days; Q3D= every 3 days; QD=every day; QW=every week. *Lines represent arithmetic mean
values, upper and lower bands represent the 95th and 5th percentiles respectively.
Table 2
Exposure parameters comparing weekly or every-2-week dosing of Ig20Gly at
130% of the monthly IVIG dose with once-monthly IVIG 10% (N=1000).
Parameter Mean CV% Minimum Median Maximum
Weekly administration
Ig20Gly, 20% weekly
Cmax, g/L 18.3 48.8 4.78 16.8 79.53
AUC0–672, g·h/L 8830 48.3 2433 8010 40,199
Ctrough, g/L 13.03 50.7 2.71 11.6 41.6
IVIG, 10% monthly
Cmax, g/L 23.1 46.2 5.63 21.21 89.14
AUC0–672, g·h/L 8974 43.1 2358 8274 29,702
Ctrough, g/L 9.78 60.0 1.96 8.85 30.1
Biweekly administration
Ig20Gly, 20% every 2 wk
Cmax, g/L 18.3 49.8 3.15 16.6 65.5
AUC0–672, g·h/L 8861 50.05 1446 7932 30,046
Ctrough, g/L 12.8 54.1 1.91 11.2 49.7
IVIG, 10% monthly
Cmax, g/L 23.5 48.5 4.40 21.2 75.8
AUC0–672, g·h/L 9096 46.1 2182 8280 29,522
Ctrough, g/L 9.73 53.5 2.03 8.46 40.9
AUC0–672= area under the concentration-time curve from time 0–672 h
(672 h=28 days); Cmax=maximum concentration; Ctrough= observation at
672 h; CV%=coeﬃcient of variation; IVIG= intravenous immunoglobulin.
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dosing have since reduced the dose adjustment factor from 1.53 to 1.37,
relative to the prior IVIG dose [5]. Less concentrated IG products (SCIG
10%) also require a dose adjustment factor of 1.37 to achieve bioe-
quivalence when patients switch to weekly SCIG therapy from monthly
IVIG administration [19,20].
It should be noted that the clinical relevance of equivalent AUCs has
not been proven. However, higher IgG trough levels have been asso-
ciated with lower rates of infection with IVIG and SCIG administrations
[21,22]. The European Medicines Agency requires that trough levels
are non-inferior to those of IVIG and does not recommend an initial
dose adjustment [3,4]. Although there is utility in estimates for popu-
lation PK parameters to guide evidence-based decisions, IG replacement
therapy must still be individually tailored [23]; there is increasing
evidence that the IG dose needed to prevent infection varies with each
patient [24,25]. Data suggest a wide range of steady-state serum IgG
levels required in patients with PID [26], and individual patients may
have their own biological IgG trough level that is essential to prevent
infection [25,27]. Thus, each patient's dose should be individualized,
taking into consideration the IgG trough levels and the clinical re-
sponse.
5. Conclusions
In summary, the population PK model based on weekly dosing data
from two phase 2/3 clinical trials in patients with PID treated with
Ig20Gly showed that the model population estimate for Ig20Gly bioa-
vailability was 73.9%. A conversion factor of 1.30 for Ig20Gly provided
comparable exposure to IVIG therapy. Ig20Gly provided equivalent
exposure when given daily to every 2 weeks supporting ﬂexible dosing
of Ig20Gly, which may translate to greater patient convenience and
provide more options for individualized dosing schedules.
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